

Monthly Update – April 2018

Fund at a Glance

Fund Size	AU\$260m
Strategy FUM	AU\$329m
Fund Inception Date	August 2012
Fund Strategy	Equity Market Neutral
Application/Redemption	Daily
Management Fee	1.5%
Performance Fee	20%
Benchmark	RBA Cash Rate


Return Characteristics¹

Positive Months	67%
Beta	-0.2%
Sharpe Ratio	1.3
Sortino Ratio	3.9
Standard Deviation (annualized)	6.7%
No. Long Positions	79
No. Short Positions	78
Gross Exposure	192%
International Exposure (% of Gross)	17.5%


Performance

	1 Mth	1 Yr	2 Yrs (pa)	3 Yrs (pa)	4 Yrs (pa)	5 Yrs (pa)	SI (pa)
WMNT (net return)	0.2%	1.9%	3.3%	7.7%	5.0%	8.8%	10.8%
RBA Cash Rate	0.1%	1.5%	1.5%	1.7%	1.9%	2.0%	2.2%
Outperformance	0.1%	0.4%	1.8%	6.0%	3.1%	6.8%	8.6%

Sector Exposures



Long/Short Spread²



Gross Portfolio Structure

	March 2018		April 2018	
Investment Type	\$m	%	\$m	%
Listed Securities - Long	243.0	94.2	261.6	100.6
Listed Securities - Short	-228.8	-88.7	-238.2	-91.6
Net Exposure	13.9	5.4	23.4	9.0
Cash	244.1	94.6	236.6	91.0
Capital	258	100	260	100

¹ Return Characteristics are for the period since inception. The Fund's inception date is August 2012.

² The Fund makes a profit where the long portfolio outperforms the short portfolio, after the payment of fees. Portfolio returns are before fees and costs.

Month in Review

April was a strong month for the Australian share market which bucked the recent trend to finish the month up almost 4%. A benign outlook for inflation, modest growth in employment and consumer spending and a slowing residential housing market provided little to excite investors in shares. The beleaguered banking and financial services sector was an additional weight on the domestic share market, which was strong nevertheless, lead higher by buoyant prices in mining and energy shares. Global markets also posted solid gains, particularly in Europe where investors looked through political instability and the lingering threat of protectionist policies, pushing major indices higher.

The Fund posted a 0.2% net return after all fees in the month. Unfortunately, two of the Fund's shorts received take-over offers, which weighed on returns. In both cases, the commercial and strategic benefits for the bidders are difficult to discern, exemplifying an inherent risk of short selling, to which the funds are exposed.

A small position in Australian wealth manager AMP was a detractor from returns in April, with shares falling almost 20% in the month. The company suffered considerable negative publicity as a result of the Royal Commission into misconduct in the Banking, Superannuation and Financial Services industry. We added to our position towards the end of the month, on the view that current prices represent considerable value and that the new Chairman David Murray is an excellent candidate to rebuild the company's reputation with customers, the regulator, and the stock market.

The strongest contributors to returns in the Consumer portfolio came from fast-growing companies: Aristocrat Leisure and Treasury Wine Estates. Aristocrat shares rallied in response to the release of a survey of US slot managers revealing that the current product portfolio remains the top performer in the industry. Treasury Wine Estate's shares were buoyed by the news that the 2018 vintage would be strong for the third year in a row, with yield and quality comparable to that seen in 2016.

The Fund's TMT portfolio performed strongly, despite increasing volatility in the technology sector. Domestically the top contributor to performance was our core investment in MYOB Group, which rallied along with the global software sector. Investments in Fairfax and APN Outdoor were beneficiaries from a shift in media spending, out of online and into traditional media. Internationally, gains were posted from both the long and short portfolios.

Domestic healthcare shares materially outperformed global peers, with European companies catching a long-awaited bid on a weaker Euro, while US biopharma shares slid ahead of US President Trump's key drug pricing speech due early May. March quarter financial reporting was a dominant feature offshore and results were generally above expectations. M&A activity continues to accelerate, boosting small-mid-sized company valuations. The Healthcare portfolio remains balanced; however, we hold a net short bias to larger biopharmaceutical companies. Medical device and life sciences company valuations may appear full however we see a longer cycle ahead for these businesses as consumer and industrial end markets remain strong. Healthcare shares delivered the strongest contribution to returns to the Fund in April with investments in CSL Ltd, Ramsay Healthcare and Merck & Co.

In Basic Industries, positive economic data out of China provided a shot in the arm for mining shares. Countering this was the rally in the US dollar, which could weigh on emerging market economies and prices of commodities. As such, we took profits and are neutral in the mining sector. Oil prices continued to rise in the month in anticipation of President Trump's decision to withdraw from the Iran nuclear deal. We retained our net long exposure to energy companies as they have lagged the advance in the oil price. Aluminium markets soared on supply outages in Brazil, as well as unexpected sanctions on Russian producer Rusal. This benefitted our holding in South32. An investment in Woodside Petroleum performed well as merits of its recent acquisition become clearer. Oil Search shares also jumped on increases in the company's Alaskan oil resource.

Monthly Net Performance (%)

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD
2012	-	-	-	-	-	-	-	1.36	0.97	0.00	6.51	2.88	11.72
2013	-0.71	0.21	4.60	1.55	5.83	5.31	1.11	2.57	1.43	1.86	0.35	-0.06	24.05
2014	1.71	1.45	-1.17	2.80	1.21	0.84	-4.38	-1.77	2.52	-1.57	-1.58	-1.32	-1.26
2015	-1.18	0.70	3.23	0.96	-0.61	3.39	3.82	4.04	2.73	-1.36	1.53	2.93	20.19
2016	-0.14	-1.93	1.13	0.53	1.08	1.76	0.60	-1.46	2.23	-0.34	-0.46	0.07	3.03
2017	-0.81	0.02	0.76	1.13	0.61	0.19	-0.39	-0.75	0.34	-1.14	1.00	0.69	1.65
2018	-0.86	0.80	1.23	0.23									1.40



Macquarie Wrap

BT Wrap

BT Panorama

Asgard

Netwealth

IOOF Pursuit

Mason Stevens

Powerwrap

Hub24

AMP North

More Information

Rani Singh – Business Development Manager

02 8047 7744

0422 745 731

singh@wfunds.com.au

www.wfunds.com.au

Link Fund Solutions – Unit Registry

LFS_contact@linkgroup.com

<http://www.linkfundsolutions.com/>

Disclaimer: This document is issued by Watermark Funds Management Pty Ltd (ABN 98 106 302 505, AFSL 250897) in relation to the Watermark Market Neutral Trust (the Fund). Watermark Funds Management Ltd (Watermark) is a privately owned funds management business. Equity Trustees Limited (ABN 46 004 031 298, AFSL 240975) is the Responsible Entity for the Fund. The information provided is general information only. It does not constitute financial, tax or legal advice or an offer or solicitation to subscribe for units or shares in any fund of which Watermark is the contracted Investment Manager. The information in this document has been prepared without taking account of your objectives, financial situation or needs. Before acting on the information or deciding whether to acquire or hold a product, consider its appropriateness and the relevant Product Disclosure Statement (PDS), which is available on Watermark's website; wfunds.com.au, or by phoning 02 92550225. Watermark receives management and performance fees in respect of the Fund, details of which are also set out in the PDS. Watermark, its affiliates and associates accept no liability for any inaccurate, incomplete or omitted information of any kind or any losses caused by using this information. All investments carry risks. There can be no assurance that any Watermark Fund will achieve its targeted rate of return and no guarantee against loss resulting from an investment in the Fund. Past fund performance is not indicative of future performance.